IL-4 and IL-13 Induce Protection of Porcine Endothelial Cells from Killing by Human Complement and from Apoptosis through Activation of a Phosphatidylinositide 3-Kinase/Akt Pathway1
暂无分享,去创建一个
A. Dalmasso | Jeremy L. Fogelson | B. Benson | B. Levay-Young | J. Grehan | Vanessa François-Bongarçon
[1] S. Miyagawa. [Complement regulatory proteins]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.
[2] Ju-Hyun Kim,et al. RANKL regulates endothelial cell survival through the phosphatidylinositol 3′‐kinase/Akt signal transduction pathway , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[3] T. Takano,et al. p38 mitogen-activated protein kinase protects glomerular epithelial cells from complement-mediated cell injury. , 2003, American journal of physiology. Renal physiology.
[4] A. Dalmasso,et al. Characteristics of CD59 up‐regulation induced in porcine endothelial cells by αGal ligation and its association with protection from complement , 2003, Xenotransplantation.
[5] Achsah D. Keegan,et al. Interleukin-4 and Interleukin-13 Signaling Connections Maps , 2003, Science.
[6] Tamar Geiger,et al. Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. , 2002, Biochemistry.
[7] I. T. Ten Berge,et al. Role of complement in graft rejection after organ transplantation. , 2002, Transfusion medicine reviews.
[8] B. van de Water,et al. The membrane attack complex of complement induces caspase activation and apoptosis , 2002, European journal of immunology.
[9] H. Rus,et al. C5b-9 Terminal Complement Complex Protects Oligodendrocytes from Death by Regulating Bad Through Phosphatidylinositol 3-Kinase/Akt Pathway1 , 2001, The Journal of Immunology.
[10] Zvi Fuks,et al. Endothelial Apoptosis as the Primary Lesion Initiating Intestinal Radiation Damage in Mice , 2001, Science.
[11] Z. Fishelson,et al. Involvement of the ERK mitogen‐activated protein kinase in cell resistance to complement‐mediated lysis , 2001, Clinical and experimental immunology.
[12] P. Evans,et al. Interleukin-13 protects endothelial cells from apoptosis and activation: association with the protective genes A20 and A1. , 2000, Transplantation.
[13] J. Pober,et al. A Phosphatidylinositol 3-Kinase/Akt Pathway, Activated by Tumor Necrosis Factor or Interleukin-1, Inhibits Apoptosis but Does Not Activate NFκB in Human Endothelial Cells* , 2000, The Journal of Biological Chemistry.
[14] W. Sessa,et al. Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt. , 2000, Circulation research.
[15] J. Pober,et al. IL-11 Activates Human Endothelial Cells to Resist Immune-Mediated Injury , 2000, The Journal of Immunology.
[16] A. Dalmasso,et al. Resistance Against the Membrane Attack Complex of Complement Induced in Porcine Endothelial Cells with a Galα(1–3)Gal Binding Lectin: Up-Regulation of CD59 Expression1 , 2000, The Journal of Immunology.
[17] D. Haskard,et al. TNF-α, IL-4, and IFN-γ Regulate Differential Expression of P- and E-Selectin Expression by Porcine Aortic Endothelial Cells1 , 2000, The Journal of Immunology.
[18] R. Kitsis,et al. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. , 2000, Circulation.
[19] J. Kim,et al. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway. , 2000, Circulation research.
[20] Y. Fujio,et al. Akt Mediates Cytoprotection of Endothelial Cells by Vascular Endothelial Growth Factor in an Anchorage-dependent Manner* , 1999, The Journal of Biological Chemistry.
[21] T. Badea,et al. Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase. , 1999, Atherosclerosis.
[22] J. Loscalzo,et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. , 1998, Blood.
[23] J. Volanakis. The human complement system in health and disease , 1998 .
[24] J. Platt,et al. Endothelial Cell Responses to Complement Activation , 1998 .
[25] N. Christou,et al. Endothelial Cells: Role in Infection and Inflammation , 1998, World Journal of Surgery.
[26] J. Beranek. Apoptosis is the main mechanism of cardiomyocyte death in the hyperacute rejection of heart xeno- and allografts. , 1997, Transplantation.
[27] D. Candinas,et al. Accommodation of vascularized xenografts: Expression of “protective genes” by donor endothelial cells in a host Th2 cytokine environment , 1997, Nature Medicine.
[28] C. Stocker,et al. In vitro accommodation of immortalized porcine endothelial cells: resistance to complement mediated lysis and down-regulation of VCAM expression induced by low concentrations of polyclonal human IgG antipig antibodies. , 1996, Transplantation.
[29] B. Benson,et al. Human IgM xenoreactive natural antibodies can induce resistance of porcine endothelial cells to complement‐mediated injury , 1996 .
[30] M. Peterson,et al. Induction of Endothelial Cell Apoptosis by TNFα: Modulation by Inhibitors of Protein Synthesis , 1994 .
[31] J. Halperin,et al. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells , 1994, The Journal of experimental medicine.
[32] K Y Hui,et al. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.
[33] C. Löwik,et al. Quantification of adherent and nonadherent cells cultured in 96-well plates using the supravital stain neutral red. , 1993, Analytical biochemistry.
[34] Z. Fishelson,et al. Sublytic complement attack protects tumor cells from lytic doses of antibody and complement , 1992, European journal of immunology.
[35] M. Shin,et al. Multiple signal messengers generated by terminal complement complexes and their role in terminal complement complex elimination. , 1990, Journal of immunology.
[36] B. Morgan. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. , 1989, The Biochemical journal.
[37] A. Michael,et al. Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. , 1983, The Journal of clinical investigation.
[38] J. Platt,et al. Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. , 1992, The American journal of pathology.
[39] J. Platt,et al. Transplantation of discordant xenografts: a review of progress. , 1990, Immunology today.